Amoxicillin/omeprazole/rifabutin

Drug Profile

Amoxicillin/omeprazole/rifabutin

Alternative Names: Amoxicillin/pantoprazole/rifabutin; Amoxicillin/rifabutin/omeprazole; Heliconda; Omeprazole/amoxicillin/rifabutin; RHB-105; Rifabutin/amoxicillin/omeprazole

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Centre for Digestive Diseases
  • Developer RedHill Biopharma
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antibacterials; Antituberculars; Antiulcers; Benzimidazoles; Gastric antisecretories; Penicillins; Rifamycins; Small molecules
  • Mechanism of Action Cell wall inhibitors; Protein 50S ribosomal subunit inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Helicobacter infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Helicobacter infections

Most Recent Events

  • 16 Nov 2016 RedHill Biopharma concludes a Type B meeting with the US FDA for amoxicillin/omeprazole/rifabutin in Helicobacter pylori infections
  • 26 Jul 2016 RedHill Biopharma announces intention to submit NDA to US FDA
  • 08 Mar 2016 Final adverse events data from a phase III ERADICATE Hp trial in Helicobacter pylori infections released by RedHill Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top